Shares of U.S. pharmaceutical giant Eli Lilly (NYSE: LLY) climbed 2.09% on Tuesday, outperforming the slightly negative S&P 500 and hitting a new annual high. The surge was driven by growing optimism around the accelerated approval timeline for its next-generation weight-loss drug and a major manufacturing expansion plan.
According to recent reports, Eli Lilly’s experimental oral weight-loss drug, orforglipron, may qualify for an expedited review pathway under the FDA’s Commissioner’s National Priority Voucher program. If accepted, the drug’s approval process could be shortened to just 1–2 months, far less than the standard 10-month.
Jefferies analyst Akash Tiwari emphasized that orforglipron meets all key criteria for priority review, citing its focus on a high-burden chronic condition and competitive pricing strategy. Phase III trial data showed participants achieved an average weight loss of over 12% after 72 weeks of treatment.
Simultaneously, Eli Lilly announced a $5 billion investment to establish a new manufacturing facility in Virginia, dedicated primarily to producing antibody-drug conjugates (ADCs). This move is part of the company’s broader $50 billion capital expansion program launched in 2020, aimed at scaling production capacity to meet soaring demand.
Goldman Sachs Research estimates the global weight-loss drug market could grow from $28 billion this year to $95 billion by 2030. Growing celebrity endorsements—such as those from tennis star Serena Williams—and expanding applications for GLP-1 receptor agonists (like Lilly’s Mounjaro and Zepbound) are fueling demand. Zepbound, approved for weight loss, and Mounjaro, for type 2 diabetes, drove a 38% revenue surge for Lilly in Q2.
Though orforglipron’s efficacy (12% weight loss) trails that of injectable alternatives (15%), its oral formulation offers distinct advantages: no dietary restrictions, lower production costs, and easier distribution—making it particularly suitable for low- and middle-income markets. In contrast, Novo Nordisk’s oral Wegovy requires fasting and involves more complex peptide-based manufacturing.
After recent market adjustments, Eli Lilly’s forward P/E ratio has dropped to 33 from over 60 last year. Given the strong growth outlook for the weight-loss drug industry and Lilly’s robust pipeline, many analysts view this valuation as an attractive entry point. The company remains a top pick among industry leaders, with its oral drug candidate expected to further solidify its market position.
